List of Gvoke Hypopen drug patents

Gvoke Hypopen is owned by Xeris.

Gvoke Hypopen contains Glucagon.

Gvoke Hypopen has a total of 1 drug patent out of which 0 drug patents have expired.

Gvoke Hypopen was authorised for market use on 10 September, 2019.

Gvoke Hypopen is available in solution;subcutaneous dosage forms.

Gvoke Hypopen can be used as treatment of severe hypoglycemia.

The generics of Gvoke Hypopen are possible to be released after 22 April, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364 XERIS Methods for producing stable therapeutic formulations in aprotic polar solvents
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic